The AAM has filed an amicus brief with the US Supreme Court in an attempt to ensure that the BPCIA biosimilars pathway remains undisturbed by the Court’s decision on the constitutionality of the ACA, also known as Obamacare.

Biocon is actively expanding its biosimilars manufacturing capacity with an aim to further penetrate EU markets after receiving a GMP approval for a key manufacturing site. The company has ramped up production for trastuzumab and pegfilgrastim, while awaiting approval for bevacizumab.

Aiming to “aggressively expand sales,” Amneal has announced that it will be launching 15 new generics by August 2021. Amneal’s generics business has also reported growth beyond its set targets for the first quarter of 2020.

Towa says it expects consolidating the Pensa business it acquired earlier this year to boost its sales by more than a third in its current financial year. Meanwhile, the Japanese firm has reported sales ahead by 5% in the year ended March 2020 on the back of new launches, as well as growth in profits despite local price cuts.

Despite reporting 14% growth in the first quarter of 2020, Endo has forecast a downturn in the second quarter and has withdrawn its full-year financial guidance due to uncertainty regarding the continued impact of the coronavirus pandemic.

Alvotech’s AVT02 proposed adalimumab biosimilar has seen positive results from two clinical trials. The high concentration dosage form of AVT02 differentes it from most of its biosimilar competitors.